LIXTW
Income statement / Annual
Last year (2023), Lixte Biotechnology Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Lixte Biotechnology Holdings, Inc.'s net income was -$5.09 M.
See Lixte Biotechnology Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$200,000.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$200,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
| Research and Development
Expenses |
$898,100.00
|
$1.35 M
|
$1.74 M
|
$1.22 M
|
$820,906.00
|
$40,703.00
|
$467,258.00
|
$1.30 M
|
$2.09 M
|
$1.12 M
|
| General & Administrative
Expenses |
$4.19 M
|
$4.96 M
|
$4.98 M
|
$2.01 M
|
$1.67 M
|
$2.10 M
|
$1.34 M
|
$833,782.00
|
$754,440.00
|
$1.29 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$4.19 M
|
$4.96 M
|
$4.98 M
|
$2.01 M
|
$1.67 M
|
$2.10 M
|
$1.34 M
|
$833,782.00
|
$754,440.00
|
$1.29 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$33,806.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$74,000.00 |
| Operating Expenses |
$5.09 M |
$6.31 M |
$6.72 M |
$3.27 M |
$2.49 M |
$2.14 M |
$1.81 M |
$2.13 M |
$2.85 M |
$2.40 M |
| Cost And Expenses |
$5.09 M |
$6.31 M |
$6.72 M |
$3.27 M |
$2.49 M |
$2.14 M |
$1.81 M |
$2.13 M |
$2.85 M |
$2.40 M |
| Interest Income |
$1,253.00 |
$11,195.00 |
$626.00 |
$5,232.00 |
$49,723.00 |
$4,923.00 |
$1,375.00 |
$183.00 |
$78.00 |
$66.00 |
| Interest Expense |
$0.00 |
$8,875.00 |
$7,414.00 |
$3,674.00 |
$0.00 |
$4,923.00 |
$1,375.00 |
$183.00 |
$78.00 |
$66.00 |
| Depreciation &
Amortization |
$5.09 M
|
$6.31 M
|
$6.72 M
|
$3.27 M
|
$2.49 M
|
$2.14 M
|
$1.81 M
|
$2.13 M
|
$205,773.00
|
$363,111.00
|
| EBITDA |
$3,207.00
|
-$1,054.00
|
-$7,951.00
|
$1,558.00
|
-$2.49 M
|
$4,923.00
|
$1,375.00
|
$183.00
|
-$2.44 M
|
-$2.40 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-12.2 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-13.23
|
0
|
| Total Other
Income/Expenses Net |
$3,207.00
|
-$1,054.00
|
-$7,951.00
|
$1,558.00
|
$49,723.00
|
$4,923.00
|
$1,375.00
|
$183.00
|
-$205,695.00
|
-$363,045.00
|
| Income Before Tax |
-$5.09 M |
-$6.31 M |
-$6.73 M |
-$3.26 M |
-$2.44 M |
-$2.13 M |
-$1.81 M |
-$2.13 M |
-$2.85 M |
-$2.77 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-14.26
|
0
|
| Income Tax Expense |
$0.00 |
-$7,821.00 |
$6,788.00 |
-$1,558.00 |
-$49,723.00 |
-$9,846.00 |
-$1,809.79 |
-$2,134.92 |
-$78.00 |
-$66.00 |
| Net Income |
-$5.09 M |
-$6.30 M |
-$6.74 M |
-$3.26 M |
-$2.39 M |
-$2.13 M |
-$1.81 M |
-$2.13 M |
-$2.85 M |
-$2.77 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-14.26 |
0 |
| EPS |
-2.66 |
-39.85 |
-5 |
-2.89 |
-2.14 |
-2.18 |
-1.94 |
-2.68 |
-3.66 |
-3.74 |
| EPS Diluted |
-2.66 |
-39.85 |
-5 |
-2.89 |
-2.14 |
-2.18 |
-1.94 |
-2.68 |
-3.66 |
-3.74 |
| Weighted Average Shares
Out |
$1.91 M
|
$158,202.00
|
$1.35 M
|
$1.13 M
|
$1.12 M
|
$979,935.00
|
$930,000.00
|
$797,000.00
|
$779,000.00
|
$740,000.00
|
| Weighted Average Shares
Out Diluted |
$1.92 M
|
$158,202.00
|
$1.35 M
|
$1.13 M
|
$1.12 M
|
$979,935.00
|
$930,290.00
|
$797,930.00
|
$779,891.00
|
$740,092.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
